Real-World Experience with TRK Inhibitors in Patients with Lung and Colon CancersVideo Categories: NTRK Gene Fusions
Dr Mary Fidler of Rush University Medical Center, Chicago, IL, and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, describe their practical experiences with TRK inhibitors in patients with lung cancer and colorectal cancer.
Sunil Verma, MD, MSEd, FRCPC discusses new classes of therapies for HR+ Breast Cancer.
Ixazomib may have the potential for great combinability with other drugs, according to Dixie-Lee Esseltine, MD and George Mulligan, PhD. Combination therapy improves compliance, adherence, and quality of life among patients.